Interest in carbohydrate antigens grows with Siamab acquisition

Siamab's acquisition by an undisclosed pharma is the latest example of pharma's growing interest in targeting sugar groups to treat cancer. The announcement comes less than two years after the biotech teamed up with Boehringer to go after carbohydrate antigens.

Siamab Therapeutics Inc. (Newton, Mass.), which has about $12 million in funding from angel investors, announced Monday it would be acquired by an undisclosed biopharma company for up to $202 million in upfront and milestone payments...